Your browser doesn't support javascript.
loading
The risk of symptomatic reinfection during the second COVID-19 wave in individuals previously exposed to SARS-CoV-2
Mattia Manica; Serena Pancheri; Piero Poletti; Giulia Giovanazzi; Giorgio Guzzetta; Filippo Trentini; Valentina Marziano; Marco Ajelli; Maria Grazia Zuccali; Pier Paolo Benetollo; Stefano Merler; Antonio Ferro.
Afiliación
  • Mattia Manica; Bruno Kessler Foundation
  • Serena Pancheri; APSS (Azienda Provinciale per i Servizi Sanitari), Trento, Italy
  • Piero Poletti; Bruno Kessler Foundation
  • Giulia Giovanazzi; APSS (Azienda Provinciale per i Servizi Sanitari), Trento, Italy
  • Giorgio Guzzetta; Bruno Kessler Foundation
  • Filippo Trentini; Bruno Kessler Foundation
  • Valentina Marziano; Bruno Kessler Foundation
  • Marco Ajelli; Indiana University School of Public Health, Bloomington, IN, USA
  • Maria Grazia Zuccali; APSS (Azienda Provinciale per i Servizi Sanitari), Trento, Italy
  • Pier Paolo Benetollo; APSS (Azienda Provinciale per i Servizi Sanitari), Trento, Italy
  • Stefano Merler; Bruno Kessler Foundation
  • Antonio Ferro; APSS (Azienda Provinciale per i Servizi Sanitari), Trento, Italy
Preprint en En | PREPRINT-MEDRXIV | ID: ppmedrxiv-21255502
ABSTRACT
To what extent infection with SARS-CoV-2 protects against subsequent reinfection or symptomatic reinfection is still unclear. In this cohort study, we analyzed surveillance records of COVID-19 cases identified between June 2020 and January 2021 in five Italian municipalities, where 77.7% of the entire population was screened for IgG antibodies in May 2020. We compared the risk of observing symptomatic infections in two mutually exclusive groups defined by the initial serological response. We estimated that the cumulative incidence of identified symptomatic infections in the IgG negative and positive cohorts was 2.67% (95%CI 2.12% - 3.37%) and 0.14% (95%CI 0.04% - 0.58%), respectively. The adjusted odd ratio of developing symptomatic infection in individuals previously exposed to SARS-CoV-2 was estimated at 0.054 (95%CI 0.009 - 0.169). Quantifying protective immunity against COVID-19 disease elicited by natural infection with SARS-CoV-2 is essential to inform strategies for controlling the pandemic in the forthcoming months.
Licencia
cc_by_nc_nd
Texto completo: 1 Colección: 09-preprints Base de datos: PREPRINT-MEDRXIV Tipo de estudio: Cohort_studies / Experimental_studies / Observational_studies / Prognostic_studies / Rct Idioma: En Año: 2021 Tipo del documento: Preprint
Texto completo: 1 Colección: 09-preprints Base de datos: PREPRINT-MEDRXIV Tipo de estudio: Cohort_studies / Experimental_studies / Observational_studies / Prognostic_studies / Rct Idioma: En Año: 2021 Tipo del documento: Preprint